A new study published in the journal PLoS ONE has reported on the first human tests of an experimental therapy using sound and light to treat Alzheimer’s disease (AD). New Atlas reports: Over the last seven years, Li-Huei Tsai and colleagues at MIT’s Picower Institute for Learning and Memory […]
Category: Alzheimer’s Disease
Cognetivity Neurosciences to Present Research Findings at AAIC 2022 Conference
The Company’s Recent Study Results will be Presented at the AAIC 2022 Conference in San Diego, California Demonstrating how its CognICA TM Tool Can Lead to Earlier Diagnosis of Dementia and Alzheimer’s Disease and Improve Health Economics of Disease Detection VANCOUVER, BC, May 31, 2022 /CNW/ – Cognetivity Neurosciences […]
Cumulus Neuroscience commences clinical studies of digital biomarker platform in degenerative neurological diseases
Cumulus’ integrated platform combines multiple digital Central Nervous System (CNS) measurement tools with AI analytics The platform enables real-world, longitudinal assessments of disease progression to accelerate CNS clinical trials CNS-101 and CNS-102 studies will assess the platform in early-stage Alzheimer’s Disease (AD) dementia, Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal […]
Cumulus Neuroscience commences clinical studies of digital biomarker platform in degenerative neurological diseases
Cumulus’ integrated platform combines multiple digital Central Nervous System (CNS) measurement tools with AI analytics The platform enables real-world, longitudinal assessments of disease progression to accelerate CNS clinical trials CNS-101 and CNS-102 studies will assess the platform in early-stage Alzheimer’s Disease (AD) dementia, Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal […]
Cumulus Neuroscience commences clinical studies of digital biomarker platform in degenerative neurological diseases
Cumulus’ integrated platform combines multiple digital Central Nervous System (CNS) measurement tools with AI analytics The platform enables real-world, longitudinal assessments of disease progression to accelerate CNS clinical trials CNS-101 and CNS-102 studies will assess the platform in early-stage Alzheimer’s Disease (AD) dementia, Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal […]
Cognetivity Neurosciences Publishes Peer-Reviewed Article Further Validating Unique Capabilities of its CognICA™ Platform for Brain Health Screening
The Company’s FDA Registered CognICA TM Tool Demonstrates How its Patented use of Animacy Recognition Improves Early Detection of Brain Health Issues Including Alzheimer’s Disease and Other Mild Cognitive Impairments VANCOUVER, BC, May 12, 2022 /CNW/ – Cognetivity Neurosciences Ltd. (“Cognetivity” or the “Company”) (CSE: CGN) (OTCQB: CGNSF) (FRA: […]
Alzamend Neuro Announces Full Data Set From Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Data confirm the positive topline results announced in December 2021 demonstrating AL001 in plasma is bioequivalent to the marketed lithium carbonate product Results show that the shapes of the lithium plasma concentration versus time curves are similar to marketed product ATLANTA, March 28, 2022 –( BUSINESS WIRE )– Alzamend […]
Intranasal delivery of pro-resolving lipid mediators arrests memory loss in experimental Alzheimer’s model
A research collaboration between scientists at LSU Health New Orleans and the Karolinska Institutet in Sweden has found that applying specialized pro-resolving lipid mediators intranasally arrested memory loss and brain degeneration in an experimental model of Alzheimer’s Disease (AD). The results are published in the Nature journal, Communications Biology […]
Neuroscientists identify mechanism for long term memory storage
A University of Iowa neuroscience research team has identified a fundamental biochemical mechanism underlying memory storage and has linked this mechanism to cognitive deficits in mouse models of Alzheimer’s Disease and Related Dementias. While working to understand how memories are formed and stored in the brain, the team identified […]
Six New Plasma Biomarkers Could Improve Diagnosis of Alzheimer’s Disease
Researchers identified six novel plasma, cell-free messenger RNA (cf-mRNA) measures as potential future biomarkers that could improve the diagnosis of Alzheimer’s disease (AD) in African Americans, according to results published online on eBioMedicine on March 17. “The clinical diagnosis of AD is challenging due to other dementias that share […]